These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31166139)

  • 21. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A local experience of treatment response in chronic hepatitis C infection.
    Bijani B; Ghanei L; Kazemifar AM
    Infez Med; 2015 Dec; 23(4):343-8. PubMed ID: 26700085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefits of hepatitis C cure with antivirals: why test and treat?
    Lledó G; Benítez-Gutiérrez L; Arias A; Requena S; Cuervas-Mons V; de Mendoza C
    Future Microbiol; 2019 Mar; 14():425-435. PubMed ID: 30900911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus: standard-of-care treatment.
    Pawlotsky JM
    Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of hepatitis C infection before and after liver transplantation.
    Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
    World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection.
    Soota K; Maliakkal B
    World J Gastroenterol; 2014 Nov; 20(43):16184-90. PubMed ID: 25473172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
    Fukasawa M
    Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus experimental model systems and antiviral drug research.
    Uprichard SL
    Virol Sin; 2010 Aug; 25(4):227-45. PubMed ID: 20960298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs.
    Naveed M; Ali A; Sheikh N; Rafique S; Idrees M
    APMIS; 2020 Apr; 128(4):326-334. PubMed ID: 31863490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C Virus-Associated Cancers.
    Yi Z; Yuan Z
    Adv Exp Med Biol; 2017; 1018():129-146. PubMed ID: 29052135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus: Promising discoveries and new treatments.
    Bastos JC; Padilla MA; Caserta LC; Miotto N; Vigani AG; Arns CW
    World J Gastroenterol; 2016 Jul; 22(28):6393-401. PubMed ID: 27605875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral treatment of hepatitis C: present status and future prospects.
    Koike K
    J Infect Chemother; 2006 Oct; 12(5):227-32. PubMed ID: 17109084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.
    He S; Lin B; Chu V; Hu Z; Hu X; Xiao J; Wang AQ; Schweitzer CJ; Li Q; Imamura M; Hiraga N; Southall N; Ferrer M; Zheng W; Chayama K; Marugan JJ; Liang TJ
    Sci Transl Med; 2015 Apr; 7(282):282ra49. PubMed ID: 25855495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.
    Ansaldi F; Orsi A; Sticchi L; Bruzzone B; Icardi G
    World J Gastroenterol; 2014 Aug; 20(29):9633-52. PubMed ID: 25110404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus.
    Shiffman ML
    Oncology; 2010 Jul; 78 Suppl 1():11-6. PubMed ID: 20616578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of hepatitis C: from empiricism to eradication.
    Pawlotsky JM
    Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.
    Kanda T; Moriyama M
    World J Gastroenterol; 2017 Aug; 23(31):5645-5649. PubMed ID: 28883690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
    Meringer H; Shibolet O; Deutsch L
    World J Gastroenterol; 2019 Aug; 25(29):3929-3940. PubMed ID: 31413528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.